

# Fritz C Eilber

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8777992/fritz-c-eilber-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71  
papers

2,423  
citations

29  
h-index

47  
g-index

74  
ext. papers

2,673  
ext. citations

4.7  
avg, IF

4.49  
L-index

#	Paper	IF	Citations
71	Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3203-9	2.2	258
70	Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. <i>Annals of Surgery</i> , <b>2007</b> , 246, 105-13	7.8	159
69	Diagnosis and management of synovial sarcoma. <i>Journal of Surgical Oncology</i> , <b>2008</b> , 97, 314-20	2.8	128
68	Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , <b>2016</b> , 7, 12783-90	3.3	99
67	Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , <b>2016</b> , 7, 47556-47564	3.3	87
66	High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. <i>Oncotarget</i> , <b>2016</b> , 7, 33046-54	3.3	86
65	Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. <i>PLoS ONE</i> , <b>2016</b> , 11, e0160882	3.7	86
64	Malignant Peripheral Nerve Sheath Tumor. <i>Surgical Oncology Clinics of North America</i> , <b>2016</b> , 25, 789-802	2.7	77
63	Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , <b>2016</b> , 7, 85929-85936	3.3	74
62	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , <b>2016</b> , 7, 71737-71743	3.3	71
61	Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , <b>2017</b> , 8, 35630-35638	3.3	68
60	Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. <i>Annals of Surgical Oncology</i> , <b>1999</b> , 6, 645-50	3.1	63
59	Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , <b>2017</b> , 8, 85516-85525	3.3	56
58	Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , <b>2017</b> , 118, 2314-2319	4.7	52
57	Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. <i>Cancer Letters</i> , <b>2018</b> , 417, 168-173	9.9	47
56	Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Cell Cycle</i> , <b>2017</b> , 16, 1164-1170	4.7	45
55	Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. <i>Oncotarget</i> , <b>2017</b> , 8, 8035-8042	3.3	44

54	A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. <i>Oncotarget</i> , <b>2017</b> , 8, 62111-62119	3.3	42
53	Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatin eradicates an osteosarcoma cisplatin-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. <i>Cell Cycle</i> , <b>2018</b> , 17, 801-809	4.7	41
52	Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. <i>Cell Cycle</i> , <b>2017</b> , 16, 91-94	4.7	37
51	The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. <i>Cell Cycle</i> , <b>2017</b> , 16, 1046-1052	4.7	35
50	High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , <b>2017</b> , 118, 2739-2743	4.7	34
49	Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , <b>2017</b> , 16, 1288-1294	4.7	34
48	Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. <i>Oncotarget</i> , <b>2018</b> , 9, 915-923	3.3	34
47	Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. <i>Oncotarget</i> , <b>2016</b> , 7, 64300-64308	3.3	33
46	Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. <i>Cell Cycle</i> , <b>2018</b> , 17, 356-361	4.7	33
45	Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , <b>2017</b> , 8, 75874-75880	3.3	32
44	The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and deletion: Direction for third-line patient therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 103129-103136	3.3	32
43	Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening. <i>Journal of Cellular Biochemistry</i> , <b>2017</b> , 118, 361-365	4.7	30
42	A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1829-1836	12.9	27
41	Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. <i>Cell Cycle</i> , <b>2017</b> , 16, 1063-1069	4.7	26
40	Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. <i>Journal of Cellular Biochemistry</i> , <b>2018</b> , 119, 3537-3544	4.7	26
39	A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatin and doxorubicin in a patient-derived orthotopic xenograft (PDOX). <i>Oncotarget</i> , <b>2017</b> , 8, 63353-63359	3.3	24
38	Advances in chemotherapy for patients with extremity soft tissue sarcoma. <i>Orthopedic Clinics of North America</i> , <b>2006</b> , 37, 15-22	3.5	23
37	Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Oncotarget</i> , <b>2018</b> , 9, 11119-11123	3.3	23

36	Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. <i>Biochemical and Biophysical Research Communications</i> , <b>2018</b> , 497, 1055-1061	3.4	22
35	Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. <i>Chemotherapy</i> , <b>2018</b> , 63, 278-283	3.2	20
34	Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , <b>2018</b> , 9, 19263-19272	3.2	19
33	Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2018</b> , 41, 1154-1161	2.7	18
32	Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. <i>Biochemical and Biophysical Research Communications</i> , <b>2018</b> , 503, 3086-3092	3.4	18
31	Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs. <i>Physics in Medicine and Biology</i> , <b>2020</b> , 65, 175006	3.8	17
30	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. <i>Biochemical and Biophysical Research Communications</i> , <b>2018</b> , 506, 912-917	3.4	17
29	Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , <b>2018</b> , 53, 30-36	2.7	15
28	Temozolomide combined with irinotecan regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. <i>Oncotarget</i> , <b>2018</b> , 9, 7774-7781	3.3	15
27	Toxicology and efficacy of tumor-targeting A1-R compared to VNP 20009 in a syngeneic mouse tumor model in immunocompetent mice. <i>Oncotarget</i> , <b>2017</b> , 8, 54616-54628	3.3	14
26	A combination of irinotecan/cisplatin and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. <i>Biochemical and Biophysical Research Communications</i> , <b>2018</b> , 505, 733-739	3.4	14
25	Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. <i>Cell Cycle</i> , <b>2018</b> , 17, 627-633	4.7	13
24	Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy. <i>Journal of Cellular Biochemistry</i> , <b>2018</b> , 119, 6598-6603	4.7	13
23	Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>BMC Cancer</i> , <b>2018</b> , 18, 840	4.8	13
22	Analysis of Stroma Labeling During Multiple Passage of a Sarcoma Imageable Patient-Derived Orthotopic Xenograft (iPDOX) in Red Fluorescent Protein Transgenic Nude Mice. <i>Journal of Cellular Biochemistry</i> , <b>2017</b> , 118, 3367-3371	4.7	12
21	Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Journal of Cellular Biochemistry</i> , <b>2018</b> , 119, 967-972	4.7	12
20	Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. <i>Oncotarget</i> , <b>2016</b> , 7, 72860-72867	3.3	12
19	Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cell Cycle</i> , <b>2018</b> , 17, 722-727	4.7	9

18	Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Journal of Drug Targeting</i> , <b>2019</b> , 27, 211-216	5.4	9
17	Pericytic mimicry in well-differentiated liposarcoma/atypical lipomatous tumor. <i>Human Pathology</i> , <b>2016</b> , 54, 92-9	3.7	9
16	Tumor-targeting A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. <i>Heliyon</i> , <b>2018</b> , 4, e00643	3.6	8
15	Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP). <i>Tissue and Cell</i> , <b>2018</b> , 54, 144-149	2.7	6
14	Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	5
13	Long-term outcomes of cement in cement technique for revision endoprosthesis surgery. <i>Journal of Surgical Oncology</i> , <b>2018</b> , 117, 443-450	2.8	5
12	Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting A1-R is superior to first-line chemotherapy. <i>Signal Transduction and Targeted Therapy</i> , <b>2018</b> , 3, 12	2.1	5
11	Low Rates of Chemotherapy Use for Primary, High-Grade Soft Tissue Sarcoma: A National Cancer Database Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1055-1065	7.3	5
10	Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
9	Sclerostin expression in skeletal sarcomas. <i>Human Pathology</i> , <b>2016</b> , 58, 24-34	3.7	4
8	[F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. <i>EJNMMI Research</i> , <b>2020</b> , 10, 122	3.6	4
7	Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. <i>Anticancer Research</i> , <b>2017</b> , 37, 4081-4084	2.3	4
6	Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. <i>Journal of Cellular Biochemistry</i> , <b>2018</b> , 119, 7827-7833	4.7	4
5	Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial network-based data augmentation. <i>Medical Physics</i> , <b>2021</b> , 48, 3262-3372	4.4	2
4	Evaluating Thresholds to Adopt Hypofractionated Preoperative Radiotherapy as Standard of Care in Sarcoma. <i>Sarcoma</i> , <b>2021</b> , 2021, 3735874	3.1	0
3	Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies. <i>Current Treatment Options in Oncology</i> , <b>2021</b> , 22, 9	5.4	0
2	High <sup>67</sup> Ga-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 1	8.8	0
1	Irregular Lipomatous Extremity Tumor. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 1718-1719	27.4	

